Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Quoin Pharmaceuticals, Ltd. American Depositary Shares (QNRX)

Surgical & Medical Instruments & Apparatus

https://www.quoinpharma.com

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

23 HATA'AS STREET
KFAR SABA, L3

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/28/2021

Market Cap

1,928,693

Shares Outstanding

990,000

Weighted SO

987,220

Total Employees

N/A

Upcoming Earnings

05/29/2017

Similar Tickers

BWV --.--%

PXMD --.--%

REVB --.--%

HILS --.--%

VRAX --.--%

NRBO --.--%

ALLR --.--%

KRBP --.--%

BDRX --.--%

Beta

2.0060

Last Div

0.0000

Range

0.4775-6.76

Chg

-0.0153

Avg Vol

44006

Mkt Cap

1928693

Exch

NASDAQ

Country

US

Phone

703 980 4182

DCF Diff

-1.7753

DCF

2.6653

Div Yield

0.0000

P/S

12.4614

EV Multiple

0.1053

P/FV

0.3272

Div Yield %

0.0000

P/E

-0.2942

PEG

-0.0051

Payout

0.0000

Current Ratio

3.3450

Quick Ratio

3.3450

Cash Ratio

0.7198

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

2931.6597

CCC

-2931.6597

Gross Margin

0.3406

Op Margin

-56.7490

Pretax Margin

-53.7475

Net Margin

-53.7475

Eff Tax Rate

-0.4827

ROA

-0.5919

ROE

-1.1211

ROCE

-0.8694

NI/EBT

1.0000

EBT/EBIT

0.9471

EBIT/Rev

-56.7490

Debt Ratio

0.0000

D/E

0.0000

LT Debt/Cap

0.0000

Total Debt/Cap

0.0000

Int Coverage

-40.1211

CF/Debt

0.0000

Equity Multi

1.8794

Rec Turnover

0.0000

Pay Turnover

0.1245

Inv Turnover

0.0000

FA Turnover

0.0000

Asset Turnover

0.0110

OCF/Share

-1.5917

FCF/Share

-1.5917

Cash/Share

2.4894

OCF/Sales

-51.9320

FCF/OCF

1.0000

CF Coverage

0.0000

ST Coverage

0.0000

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

0.3272

P/B

0.3272

P/S

12.4614

P/E

-0.2942

P/FCF

-0.2400

P/OCF

-0.3045

P/CF

-0.3045

PEG

-0.0051

P/S

12.4614

EV Multiple

0.1053

P/FV

0.3272

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 13, 08:30 Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome GlobeNewswire Inc. Nov 08, 17:46 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results GlobeNewswire Inc. Nov 08, 17:46 Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2023 Financial Results GlobeNewswire Inc. Nov 03, 08:41 Quoin Pharmaceuticals Announces Third Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday November 9th at 8:30 am ET GlobeNewswire Inc. Oct 24, 09:32 REPEAT -- Quoin Pharmaceuticals Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome

Revenue Product Segmentation